SeraGene Therapeutics

SeraGene Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation RNA interference (RNAi) therapies for severe neurological disorders. Spun out from the University of Massachusetts Chan Medical School, the company utilizes a proprietary hydrophobically modified small interfering RNA (hsiRNA) platform designed to achieve broad and efficient distribution within the central nervous system. Their lead programs target neurodegenerative conditions such as Huntington's disease and Amyotrophic Lateral Sclerosis (ALS) by silencing disease-causing genes. SeraGene aims to overcome traditional delivery barriers in the brain to provide transformative treatments for patients with limited options.